Eisai opened its European headquarters in Hatfield, UK in June 2009. The ‘European Knowledge Centre’ is made up of a manufacturing plant, research laboratory, office building and other shared facilities and will employ a total of 500 staff, including 250 newly created research positions. The company has invested around £100 million in the project.
Japan-based Eisai manufactures pharmaceuticals for conditions such as Alzheimer’s disease, Parkinson’s disease and epilepsy.
Eisai’s European regional headquarters, manufacturing subsidiary, and UK clinical research and sales subsidiary have all relocated to the new centre, and a new research centre has been added to strengthen the company’s research subsidiary at University College London.
The facility will enable the company to manufacture its own products in Europe for the first time, as previously it has relied on business alliance partner companies. Eisai will start packaging several of its products in-house by the end of the fiscal year 2009, and plans to manufacture drug formulations in the future.
Further reading - An in-depth analysis of the UK pharmaceutical market, including some background information on domestic production and multinational manufacturers, is available from Espicom: The Pharmaceutical Market: United Kingdom (published March 2009)